China SXT Pharmaceuticals (SXTC) EPS (Weighted Average and Diluted): 2017-2025
Historic EPS (Weighted Average and Diluted) for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to -$2.32.
- China SXT Pharmaceuticals' EPS (Weighted Average and Diluted) fell 14.98% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.1 million, marking a year-over-year increase of 3.94%. This contributed to the annual value of -$2.32 for FY2025, which is 91.88% up from last year.
- According to the latest figures from FY2025, China SXT Pharmaceuticals' EPS (Weighted Average and Diluted) is -$2.32, which was up 91.88% from -$28.58 recorded in FY2024.
- Over the past 5 years, China SXT Pharmaceuticals' EPS (Weighted Average and Diluted) peaked at $34.5 million during FY2021, and registered a low of -$177.84 during FY2023.
- Over the past 3 years, China SXT Pharmaceuticals' median EPS (Weighted Average and Diluted) value was -$28.58 (recorded in 2024), while the average stood at -$69.58.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first slumped by 100.00% in 2023, then skyrocketed by 91.88% in 2025.
- Yearly analysis of 5 years shows China SXT Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $34.5 million in 2021, then dropped by 2.90% to $33.5 million in 2022, then plummeted by 100.00% to -$177.84 in 2023, then surged by 83.93% to -$28.58 in 2024, then surged by 91.88% to -$2.32 in 2025.